【2024 ASCO】面面俱到：免疫治疗领域的重磅研究进展，抢先看！

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial

3期NADINA试验：新辅助纳武利尤单抗 + 伊匹木单抗与辅助纳武利尤单抗治疗肉眼可见的可切除III期黑色素瘤

讲者：Christian Blank, Netherlands Cancer Institute (NKI-AVL)

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

ADRIATIC研究：度伐利尤单抗（D）作为局限期小细胞肺癌（LS-SCLC）患者（pts）的巩固治疗（tx）

讲者：David Spigel, Sarah Cannon Research Institute

A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy

随机III期A-BRAVE试验：阿维鲁单抗治疗新辅助化疗后有残留病灶或初次手术和辅助化疗后高危的早期TNBC

讲者:  Pier Franco Conte, MD | Department of Surgery Oncology and Gastroenterology, University of Padua

Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial

I-SPY2.2试验：datopotamab deruxtecan（Dato）联合度伐利尤单抗在新辅助治疗中的pCR率

讲者: Rebecca Shatsky, University of California, San Diego Medical Center

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer

随机II期试验SACI-IO HR+：戈沙妥珠单抗±帕博利珠单抗治疗转移性HR+/HER2-乳腺癌

讲者: Ana Christina Garrido-Castro, MD | Dana-Farber Cancer Institute

Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202

EV-202研究中，TNBC和HR+/HER2-乳腺癌队列中Enfortumab vedotin (EV)的应用

讲者: Antonio Giordano, MD, PhD | Dana-Farber Cancer Institute

Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial

Claudin18.2靶向嵌合抗原受体T细胞疗法用于胃肠道肿瘤患者：CT041-CG4006 1期临床试验最终结果

讲者：齐长松——北京大学肿瘤医院

A potential best-in-class BCMA-CD19 bispecific CART with advanced safety by self-inhibiting IFNG signaling during CRS

一种潜在同类最佳BCMA-CD19双特异性CART，通过在CRS期间自我抑制IFNG信号通路，显示出较好的安全性

讲者：薛磊——安徽省立医院

Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies

抗CCR8单克隆抗体LM-108联合抗PD-1抗体用于胃癌患者的疗效和安全性：1/2期研究结果

讲者：刘畅——北京大学肿瘤医院

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW

CheckMate 8HW研究的扩展疗效分析：纳武利尤单抗+伊匹木单抗 vs 化疗一线治疗微卫星高度不稳定/错配修复缺陷(MSI-H/dMMR)转移性结直肠癌(mCRC)

讲者：Heinz-Josef Lenz, Norris Comprehensive Cancer Center, University of Southern California

NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer

NEOPRISM-CRC研究：针对高危2/3期dMMR/MSI-H结直肠癌，根据肿瘤突变负荷（TMB）对帕博利珠单抗新辅助治疗患者进行分层

讲者：Kai-Keen Shiu, University College Hospital, NHS Foundation Trust

Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study

IBI310(抗CTLA-4抗体)+信迪利单抗(抗PD-1抗体)新辅助治疗微卫星不稳定性高/错配修复缺陷结直肠癌：一项随机、开放标签、Ib期研究结果

讲者：徐瑞华——中山大学肿瘤防治中心

A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174)

纳武利尤单抗+伊匹木单抗围手术期治疗局部食管癌和胃食管结合部腺癌患者的II/III期研究：新辅助病理完全缓解（pCR）率结果（ECOG-ACRIN EA2174）

讲者：Jennifer Eads, University of Pennsylvania, Abramson Cancer Center

Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: the ARMANI phase III trial

III期ARMANI临床试验：在晚期HER2阴性胃或胃食管交界（GEJ）癌患者中，将雷莫西尤单抗联合紫杉醇作为转换维持治疗与继续使用基于奥沙利铂的化疗进行比较

讲者：Filippo Pietrantonio, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori

International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI)

瑞戈非尼+帕博利珠单抗用于既往接受过免疫检查点抑制剂（ICI）治疗的晚期肝细胞癌（HCC）患者的国际、开放标签、2期研究

讲者：Anthony El-Khoueiry, Norris Comprehensive Cancer Center, University of Southern California

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW

CheckMate 9DW研究首次结果：纳武利尤单抗+伊匹木单抗 vs 仑伐替尼/索拉非尼一线治疗不可切除肝细胞癌（uHCC）

讲者：Peter Galle, University Medical Center Mainz

Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC) 
在之前未接受治疗的局部晚期或转移性尿路上皮癌患者中，enfortumab vedotin联合帕博利珠单抗（EV+P）vs. 铂类化疗的随机3期试验的患者报告结果

讲者：Shilpa Gupta/    Taussig Cancer Institute, Cleveland Clinic 

Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer

在局部晚期或转移性尿路上皮癌患者中，enfortumab vedotin暴露对结果的影响

讲者：Daniel Petrylak/   Yale School of Medicine  

Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection

在IMmotion010中进行的循环肾脏损伤分子-1生物标志物分析：一项对切除后复发风险增加的肾细胞癌患者进行的随机3期研究，比较辅助性阿替利珠单抗与安慰剂

讲者：Laurence Albiges/Gustave Roussy, Université Paris Saclay  

Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC)

部分总生存期：在CheckMate 9ER中对4年以上生存状态的全面分析，比较一线纳武利尤单抗联合卡博替尼与舒尼替尼治疗晚期肾细胞癌

讲者：Charlene Mantia/Dana-Farber Cancer Institute  

Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 tria

从CheckMate 901试验中，对纳武利尤单抗 + 吉西他滨-铂类 vs.单独吉西他滨-铂类的完全应答者的特征，以及仅有淋巴结转移的尿路上皮癌患者的特征进行描述

讲者：Matt Galsky/ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai  

Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas

BrUOG 354的最终结果：纳武利尤单抗单独或与伊匹木单抗联合治疗卵巢和其他肾外透明细胞癌患者的随机II期试验

讲者：Don Dizon/Lifespan Cancer Institute, Rhode Island Hospital    

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study

AGO-OVAR 2.29/ENGOT-ov 34研究的最终OS和PFS结果：阿替利珠单抗与安慰剂联合贝伐珠单抗和非铂类化疗治疗复发性卵巢癌

讲者：Frederik Marmé, Heidelberg University, University Hospital Mannheim

Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study

Vibostolimab联合帕博利珠单抗（vibo/pembro）治疗既往接受过治疗的晚期错配修复缺陷（dMMR）子宫内膜癌：来自KEYVIBE-005 II期研究B1队列的结果

讲者：Carlos Rojas，Bradford Hill Clinical Research Center

Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial

卡瑞利珠单抗辅助治疗高危局部区域性晚期鼻咽癌(DIPPER)：一项多中心、开放标签、3期随机对照试验

讲者：刘需——中山大学肿瘤防治中心

Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial

替雷利珠单抗 vs 安慰剂联合诱导化疗，随后同步放化疗和替雷利珠单抗或安慰剂辅助治疗局部区域性晚期鼻咽癌：多中心，随机，安慰剂对照，双盲，3期试验中期分析结果

讲者：陈秋燕——中山大学肿瘤防治中心

Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial

恩度联合同步放化疗 vs 仅同步放化疗治疗局部晚期鼻咽癌(LA-NPC)：一项III期、前瞻性、随机对照、多中心临床试验

讲者：康敏——广西医科大学第一附属医院

Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC)

ISA101b和西米普利单抗联合治疗复发/转移性（R/M）HPV16阳性口咽癌(OPC)的随机、双盲、安慰剂对照II期研究（OpcemISA）结果

讲者：Caroline Even, Head and Neck Department, Gustave Roussy

A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC)

CUE-101 作为单药治疗并与帕博利珠单抗联合治疗复发/转移性 HPV16+ 头颈部鳞状细胞癌 （R/M HNSCC） 患者的 I期剂量递增和扩展研究

讲者：Alexander Colevas, Stanford Cancer Center

HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results

基于 HB-200 沙粒病毒的免疫疗法联合帕博利珠单抗作为复发/转移性 HPV16 阳性头颈癌患者的一线治疗：更新结果

讲者：Alan Ho, Memorial Sloan Kettering Cancer Center

A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study

一项随机、双盲、安慰剂对照的 II 期研究，比较帕博利珠单抗与安慰剂在复发风险高的头颈部鳞状细胞癌患者中的疗效：PATHWay 研究

讲者：Alexander Pearson, Department of Medicine, University of Chicago

Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia

新型CD3xCD19 IgG4双特异性抗体CN201用于复发或难治性B细胞急性淋巴细胞白血病成年患者的I期研究

讲者：王迎——中国医学科学院血液学研究所

CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma

CLAMP：卡瑞利珠单抗联合培门冬酶、依托泊苷和高剂量甲氨蝶呤治疗自然杀伤(NK)/ T细胞淋巴瘤的II期前瞻性研究

讲者：刘涛——华中科技大学同济医学院附属协和医院 

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study

III期ECHELON-3研究结果：维布妥昔单抗联合来那度胺和利妥昔单抗治疗复发性/难治性弥漫性大B细胞淋巴瘤患者

讲者：Jeong A Kim, St. Vincent’s Hospital, The Catholic University of Korea

BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC)

BEAT-SC：贝伐珠单抗或安慰剂联合阿替利珠单抗和含铂化疗治疗广泛期小细胞肺癌（ES-SCLC）患者的随机III期研究

讲者：Yuichiro Ohe, MD, PhD | National Cancer Center Hospital

BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial

BEAT—meso：贝伐珠单抗和标准化疗联合或不联合阿替利珠单抗作为晚期胸膜间皮瘤（PM）一线治疗的随机III期研究—ETOP 13—18试验结果

讲者：Sanjay Popat, PhD, FRCP | Royal Marsden Hospital NHS Foundation Trust

Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas: Results of a prospective pilot study

新辅助纳武利尤单抗和化疗治疗可切除弥漫性胸膜间皮瘤的可行性和安全性：一项前瞻性初步研究的结果

讲者：Michael Offin, MD | Memorial Sloan Kettering Cancer Center

Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study

III期可切除NSCLC患者中按淋巴结状态划分的围手术期使用纳武利尤单抗（NIVO）的临床结局：3期CheckMate 77T研究的结果

讲者：Tina Cascone, MD, PhD | The University of Texas MD Anderson Cancer Center

A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091)

一项评估局部晚期非小细胞肺癌新辅助化疗+纳武利尤单抗和同步放化疗后纳武利尤单抗巩固治疗的II期随机试验(GASTO-1091)

讲者：刘慧——中山大学肿瘤防治中心 

Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study

戈沙妥珠单抗（SG）对比多西他赛（doc）治疗既往接受过铂类化疗（PT）和PD(L)-1抑制剂（IO）治疗的转移性非小细胞肺癌（mNSCLC）患者：3期EVOKE-01研究的初步结果

讲者：Luis G. Paz-Ares, PhD | Hospital Universitario 12 De Octubre

Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study

芦康沙妥珠单抗 (SKB264/MK-2870)联合KL-A167(PD-L1单抗)一线治疗晚期NSCLC II期OptiTROP-Lung01研究

讲者：方文峰——中山大学肿瘤防治中心

Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study

Amivantamab+lazertinib vs 奥希替尼一线治疗具有高风险疾病生物标志物的EGFR突变晚期NSCLC：MARIPOSA 3期研究的二次分析

讲者：Enriqueta Felip, MD, PhD | Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology

Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial

皮下注射amivantamab vs 静脉注射amivantamab，均联合lazertinib，治疗难治性EGFR突变的晚期NSCLC：来自全球3期随机对照PALOMA-3试验的主要结果，包括总生存期（OS）

讲者：Natasha B. Leighl, MD, FASCO | Princess Margaret Cancer Centre

Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial

依沃西单抗联合化疗用于EGFR酪氨酸激酶抑制剂(HARMONi-A)治疗进展的EGFR突变非鳞状非小细胞肺癌：一项随机、双盲、多中心、3期试验

讲者：张力——中山大学肿瘤防治中心 

Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: the primary analysis of an EORTC randomized phase II study (EBIN)

在晚期BRAF-V600E/K突变黑色素瘤患者中联合使用encorafenib和 binimetinib，然后使用伊匹单抗联合纳武利尤单抗对比伊匹单抗联合纳武利尤单抗：一项EORTC随机II期研究（EBIN）的初步分析

讲者：Caroline Robert, Department of Cancer Medicine, Gustave Roussy Cancer Campus, University of Paris-Saclay

Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab（NIVO + RELA + IPI）in advanced melanoma: Results from RELATIVITY-048

纳武利尤单抗、relatlimab和伊匹单抗（NIVO + RELA + IPI）治疗晚期黑色素瘤的疗效和安全性：RELATIVITY-048的结果

讲者：Paolo Ascierto, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A

lifileucel（一种自体肿瘤浸润淋巴细胞疗法）和帕博利珠单抗治疗未使用免疫检查点抑制剂的不可切除或转移性黑色素瘤患者的疗效和安全性：IOV-COM-202 队列1A的最新结果

讲者：Sajeve Thomas, Orlando Health Cancer Institute

Triplet combination treatments with pembrolizumab（pembro） for anti–PD-（L）1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study

帕博利珠单抗（pembro）的三联疗法治疗抗PD-（L）-1难治性晚期黑色素瘤：Ⅰ/Ⅱ期KEYMAKER-U02A的初步结果

讲者：Reinhard Dummer, University Hospital Zurich

Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma（CM）

一项分析IMC-F106C（一种PRAME × CD3 ImmTAC的双特异性抗体）治疗post-checkpoint皮肤黑色素瘤（CM）的疗效和安全性的Ⅰ期研究

讲者：Omid Hamid, The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate

Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab（pem）in patients（pts）with metastatic melanoma（mMEL）with disease progression on anti–PD-1 therapy

首创CXCR1/2 SX-682联合帕博利珠单抗（pem）治疗抗PD-1治疗疾病进展转移性黑色素瘤（mMEL）的疗效和安全性

讲者：Sapna Patel, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center

SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma

SU2C-SARC032：一项针对软组织肉瘤的新辅助放疗联合或不联合帕博利珠单抗手术的随机试验

讲者：Yvonne Mowery, UPMC Hillman Cancer Center, Department of Radiation Oncology

Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), myxoid liposarcoma (MLPS) and de-differentiated liposarcoma (DDLPS): A single-arm phase 2 trial

信迪利单抗、多柔比星和异环磷酰胺(AI)用于晚期未分化多形性肉瘤(UPS)、滑膜肉瘤(SS)、黏液样脂肪肉瘤(MLPS)和去分化脂肪肉瘤(DDLPS)一线治疗：一项单臂2期试验

讲者：罗志国——复旦大学附属肿瘤医院

ImmunoSarc II master trial (phase II of sunitinib and nivolumab) : Results from the dedifferentiated chondrosarcoma （DDCS） cohort—A GEIS, ISG and UCL study

ImmunoSarc II主试验（舒尼替尼和纳武利尤单抗的II期）：来自去分化软骨肉瘤（DDCS） 队列GEIS, ISG和UCL研究的结果

讲者：Sandra Strauss, University College London Hospital NHS Trust

Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study

Sacituzumab tirumotecan (SKB264/MK-2870)用于经治局部复发或转移性三阴性乳腺癌(TNBC)患者：OptiTROP-Breast01 III期研究结果

讲者：樊英 中国医学科学院肿瘤医院   

Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)

随机化3期DREAMM-8研究结果：在复发性/难治性多发性骨髓瘤（RRMM）中，belantamab mafodotin联合泊马度胺和地塞米松（BPd）与泊马度胺联合硼替佐米和地塞米松（PVd）的比较

讲者：Suzanne Trudel, Princess Margaret Cancer Centre

Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial

TAPISTRY研究：阿替利珠单抗在肿瘤突变负荷（TMB）高肿瘤患者中的应用

讲者：Rafal Dziadziuszko, Department of Oncology & Radiotherapy and Early Phase Clinical Trials Centre, Medical University of Gdańsk

Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS)

维迪西妥单抗(RC48)联合替雷利珠单抗和S-1用于HER2过表达晚期胃或胃食管交界腺癌一线治疗的疗效：一项多中心、单臂、II期试验(RCTS)

讲者：刘联——山东大学齐鲁医院

A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study

一种新型、独特性设计的抗PD-L1和4-1BB双特异性抗体(LBL-024)用于晚期恶性肿瘤和神经内分泌肿瘤：I/II期、开放标签、多中心、剂量递增/扩展研究中LBL-024单药治疗的安全性和有效性结果

讲者：张盼盼 北京大学肿瘤医院

Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study

抗CLDN18.2/CD3双特异性抗体IBI389用于晚期胰腺导管腺癌的安全性和有效性：I期初步结果

讲者：郝继辉 天津医科大学肿瘤医院

Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy

BRIA-IMT（一种同种异体全细胞免疫治疗）治疗晚期/转移性乳腺癌的结局 

讲者:  Carmen Julia Calfa, MD | Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine

Phase 2 trial of pembrolizumab plus SurVaxM for patients with glioblastoma at first recurrence (RESURGe)

帕博利珠单抗联合SurVaxM治疗首次复发胶质母细胞瘤患者的II期试验（RESURGe）

A phase Ib, window-of-opportunity study of neoadjuvant avelumab and hypofractionated proton beam therapy for recurrent radiation-relapsed meningioma

一项新辅助阿维鲁单抗和大分割质子束治疗复发的放射性复发性脑膜瘤的Ib期、机会窗研究

Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study

抗CLDN18.2/CD3双特异性抗体IBI389用于实体瘤和胃/胃食管肿瘤患者的安全性和初步疗效：一项1期剂量递增和扩展研究

讲者：Li Zheng——四川大学华西医院 

Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC)

Sotorasib+帕尼单抗（soto+pani）的3期CodeBreak 300研究与研究者选择的KRAS G12 C突变转移性结直肠癌（mCRC）治疗的总生存期（OS）

讲者：Marwan Fakih, City of Hope Comprehensive Cancer Center

Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial

卡度尼利单抗联合pulocimab和紫杉醇用于免疫化疗失败的晚期胃或胃食管交界(G/GEJ)癌患者二线治疗的有效性和安全性：一项多中心、双盲、随机试验

讲者：张小田 北京大学肿瘤医院

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer

阿替利珠单抗+varlilumab(CDX-1127)联合/不联合考比替尼用于既往接受过治疗的不可切除胆道癌的随机2期研究

讲者：Thatcher Heumann, Vanderbilt-Ingram Cancer Center

Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment

sitravatinib+替雷利珠单抗用于既往至少接受过1次全身治疗失败的晚期胆道癌患者的II期研究

讲者：Jeesun Yoon, Department of Internal Medicine, Seoul National University Hospital; Cancer Research Institute, Seoul National University

Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial

卡瑞利珠单抗联合阿帕替尼用于经治晚期肾上腺皮质癌：单臂，开放标签，2期试验

讲者：卫治功——四川大学华西医院

Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results

SURE-01/02中期结果：围手术期sacituzumab govitecan（SG）单独或联合帕博利珠单抗（Pembro）治疗肌层浸润性尿路上皮膀胱癌（MIBC）患者

讲者：Antonio Cigliola, Medical Oncology Department, IRCCS San Raffaele Hospital

Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial

信迪利单抗+紫杉醇和顺铂用于局部晚期宫颈癌新辅助治疗的有效性和安全性：一项II期试验

讲者：刘继红——中山大学肿瘤防治中心

Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study

尼妥珠单抗+同步放化疗治疗局部晚期宫颈鳞状细胞癌：随机3期CC3研究

讲者：王俊杰——北京大学第三医院 

Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors

评估普特利单抗联合表皮生长因子受体-ADC (EGFR-ADC)药物MRG003治疗EGFR阳性实体瘤患者安全性和有效性的I/II期研究初步结果

讲者：阮丹云 中山大学肿瘤防治中心

Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study

Petosemtamab （MCLA-158） 联合帕博利珠单抗作为复发/转移 （r/m） 头颈部鳞状细胞癌 （HNSCC） 的一线 （1L） 治疗：II 期研究

讲者：Jerome Fayette, Department of Medical Oncology, Centre Léon Bérard, University of Lyon

Intralesional nivolumab in oral potentially malignant disorders: A phase 1 pilot study on safety, tolerability, and preliminary efficacy

口腔潜在恶性疾患中局部注射纳武利尤单抗的I期试点研究：安全性、耐受性和初步疗效

讲者：Shorook Naara, The University of Texas MD Anderson Cancer Center

Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV

基于HPV16特异性沙粒病毒的新辅助免疫疗法HB-200联合化疗，随后根据反应分层减量治疗HPV16阳性口咽癌：TARGET-HPV

讲者：Ari Rosenberg, University of Chicago, Department of Medicine

Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity

Timdarpacept (IMM01)联合替雷利珠单抗用于既往抗PD-1单抗治疗失败经典型霍奇金淋巴瘤：一项评估安全性和初步抗肿瘤活性得开放标签、多中心、II期研究(IMM01-04)

讲者：宋玉琴——北京大学肿瘤医院

Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816

新辅助纳武利尤单抗+化疗对比化疗在可切除NSCLC患者中的应用：CheckMate 816的4年更新

讲者：Jonathan Spicer, MD, PhD, FRCPC | McGill University Health Centre

Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN

围手术期度伐利尤单抗治疗可切除NSCLC和基线N2淋巴结受累（N2 R-NSCLC）患者的结局：AEGEAN的探索性亚组分析

讲者：John Heymach, MD, PhD | The University of Texas MD Anderson Cancer Center

Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)

围手术期帕博利珠单抗治疗早期非小细胞肺癌（NSCLC）的随机、双盲、3期KEYNOTE-671研究的健康相关生活质量（HRQoL）结局

讲者：Marina Chiara Garassino, MD | Fondazione IRCCS Istituto Nazionale dei Tumori (currently at Knapp Center for Biomedical Discovery, University of Chicago Medicine & Biological Sciences, Chicago, IL, USA)

Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer

阿得贝利单抗+化疗序贯胸部放疗一线治疗广泛期小细胞肺癌的总生存

讲者：陈大卫 山东第一医科大学附属肿瘤医院

DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC)—Efficacy and safety analyzed by presence of brain metastasis

DeLLphi-301：Tarlatamab在小细胞肺癌（SCLC）中的II期试验-通过脑转移情况分析疗效和安全性

讲者：Anne-Marie C. Dingemans, MD, PhD | Erasmus MC Cancer Institute

Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma（HCRN MEL17-309）

辅助纳武利尤单抗联合伊匹单抗治疗高危葡萄膜黑色素瘤患者的II期多中心研究（HCRN MEL17-309）

讲者：Suthee Rapisuwon, Washington Cancer Institute/Georgetown-Lombardi Comprehensive Cancer Center

Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma

一项开放标签、多中心、Ⅰ期研究，分析RP2单用或联合纳武利尤单抗治疗葡萄膜黑色素瘤患者的疗效、安全性和生物标志物结果

讲者：Joseph Sacco, The Clatterbridge Cancer Centre and University of Liverpool

Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial

个体化新抗原疗法mRNA-4157（V940）联合帕博利珠单抗治疗可切除黑色素瘤：mRNA-4157-P201（KEYNOTE-942）试验的3年更新结果

讲者：Jeffrey Weber, Perlmutter Cancer Center, NYU Langone Health

Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma（NEO-TIM）: Primary results

维莫非尼、考比替尼和阿替利珠单抗联合或序贯治疗高风险可切除黑色素瘤 （NEO-TIM）：初步结果

讲者：Paolo Ascierto, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma（cSCC）with the use of neoadjuvant pembrolizumab: De-Squamate

使用新辅助帕博利尤单抗对可切除局部晚期皮肤鳞状细胞癌（cSCC）进行降阶梯治疗的Ⅱ期研究：De-Squamate

讲者：Rahul Ladwa, Princess Alexandra Hospital and Faculty of Medicine at University of Queensland

OBX-115, an interleukin 2 （IL2）-sparing engineered tumor-infiltrating lymphocyte （TIL） cell therapy, in patients （pts） with immune checkpoint inhibitor （ICI）-resistant unresectable or metastatic melanoma

OBX-115—一种保留白介素2（IL2）的工程化肿瘤浸润淋巴细胞（TIL）细胞疗法用于治疗免疫检查点抑制剂（ICI）耐药的不可切除或转移性黑色素瘤患者 （pts）

讲者：Rodabe Amaria, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center

Phase III randomized trial evaluating tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE 301)

评估替索托莫德联合伊匹单抗对比单独伊匹单抗治疗晚期难治性黑色素瘤患者的Ⅲ期随机试验：ILLUMINATE 301 

讲者： Adi Diab, Melanoma Medical Oncology Department, University of Texas MD Anderson Cancer Center

Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial

IGNYTE临床试验中RP1联合纳武利尤单抗治疗抗PD-1失败黑色素瘤患者的疗效和安全性

讲者：Michael Wong, The University of Texas MD Anderson Cancer Center

Phase II trial, multicenter, first line paclitaxel-avelumab treatment for inoperable angiosarcoma

一线紫杉醇-阿维鲁单抗治疗不可手术的血管肉瘤：一项多中心II期试验

讲者：Hye Ryeon Kim, Dong-A University Hospital

Cemiplimab in locally advanced and/or metastatic secondary angiosarcomas （CEMangio）: A phase II clinical trial

西米普利单抗治疗局部晚期和/或转移性继发性血管肉瘤（CEMangio）：一项II期临床试验

讲者：Stefan van Ravensteijn, Radboud UMC

Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS)

Alliance A091902：一项多中心随机II期试验，紫杉醇（P）联合或不联合纳武利尤单抗（N）治疗晚期血管肉瘤（AS）患者

讲者：Juneko Grilley-Olson, Duke Cancer Institute, Duke University

A phase II study of anlotinib and an anti-PDL1 antibody in patients with alveolar soft part sarcoma: Results of expansion cohorts

安罗替尼和抗PD-1抗体治疗肺泡软组织肉瘤的II期研究：扩展队列结果

讲者：刘佳勇 北京大学肿瘤医院

Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415)

度伐利尤单抗和曲美木单抗与多柔比星在先前未经治疗的晚期或转移性软组织肉瘤患者中的疗效：随机II期MEDISARC研究（AIO-STS-0415）患者报告的结果（PROs）

讲者：Viktor Grünwald, Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Clinic for Medical Oncology, Clinic for Urology, Essen University Hospital

扫码关注专栏，与肿瘤资讯不见不散！